845280-92-4

Usage

Molecular structure

The compound has a complex structure with multiple functional groups, including a pyrrole ring, a sulfonamide group, two 4-fluorophenyl groups, a methyl group, an isopropyl group, a phenylmethyl group, and a tetrahydropyran ring.

Functional groups

The compound contains several functional groups, including a sulfonamide group at position 3 of the pyrrole ring, two 4-fluorophenyl groups at positions 4 and 5, a methyl group, an isopropyl group, and a phenylmethyl group attached to the nitrogen atom, and a tetrahydropyran ring with a hydroxyl and ketone group.

Stereochemistry

The compound has two stereo centers, with the (2R,4R) configuration.

Potential pharmaceutical activity

The presence of multiple pharmacophores in the molecule suggests potential pharmaceutical activity.

Chemical properties

The compound's chemical properties are influenced by its various functional groups, which may contribute to its potential pharmaceutical activity.

Physical properties

The physical properties of the compound, such as its solubility, melting point, and boiling point, are not provided in the material.

Molecular weight

The molecular weight of the compound is 596.66 g/mol.

Upstream product

• 845280-90-2 C₄₁H₅₀F₂N₂O₆S 

Relevant academic research and scientific papers

Risk of Late-Onset Alzheimer's Disease by Plasma Cholesterol: Rational in Silico Drug Investigation of Pyrrole-Based HMG-CoA Reductase Inhibitors

Alzheimer's disease (AD), a worldwide renowned progressive neurodegenerative disorder, is the most common cause of dementia. There are several studies on the important role of cholesterol metabolism in AD pathogenesis, which indicated that the high concen

Hepatoselectivity of statins: Design and synthesis of 4-sulfamoyl pyrroles as HMG-CoA reductase inhibitors

4-Sulfamoyl pyrroles were designed as novel hepatoselective HMG-CoA reductase inhibitors (statins) to reduce myalgia, a statin-induced adverse effect. The compounds were prepared via a [3 + 2] cycloaddition of a Muenchnone with a sulfonamide-substituted alkyne. We identified compounds with greater selectivity for hepatocytes compared to L6-myocytes than rosuvastatin and atorvastatin. There was an inverse correlation of myocyte potencies and C log P values. A number of analogs were effective at reducing cholesterol in acute and chronic in vivo models but they lacked sufficient chronic in vivo activity to warrant further development.

NOVEL PYRROLE-BASED HMG-COA REDUCTASE INHIBITORS

HMGCo-A reductase inhibitor compounds useful as hypocholesterolemic and hypolipidemic compounds are provided. Also provided are pharmaceutical compositions of the compounds. Method of making and methods of using the compounds are also provided.